Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
暂无分享,去创建一个
S. Sleijfer | J. Schellens | J. Beijnen | G. Groenewegen | E. Voest | J. Haanen | I. van der Tweel | R. Giles | N. Mehra | M. Langenberg | J. Vermaat | J. Y. Engwegen | J. Roodhart | C. Korse | W. Kruit
[1] C. Ulrich,et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Schadendorf,et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Jing Wang,et al. Proteomic studies of early-stage and advanced ovarian cancer patients. , 2008, Gynecologic oncology.
[4] S. Loening,et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. , 2008, Cancer letters.
[5] C. Charbonneau,et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.
[6] P. Sham,et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma , 2008, Journal of cellular biochemistry.
[7] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[8] J. Sandoval,et al. Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers. , 2007, The Journal of surgical research.
[9] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[10] Daniel Hartmann,et al. Identification of Potential Markers for the Detection of Pancreatic Cancer Through Comparative Serum Protein Expression Profiling , 2007, Pancreas.
[11] J. Schellens,et al. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations , 2007, Laboratory Investigation.
[12] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[13] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[14] Xun Qu,et al. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. , 2006, Gynecologic oncology.
[15] Da-Wei Gong,et al. Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications , 2006, PLoS medicine.
[16] Marie-Christine W. Gast,et al. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. , 2006, Trends in pharmacological sciences.
[17] Ziding Feng,et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. , 2005, Cancer research.
[18] S. Flibotte,et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. , 2005, Clinical chemistry.
[19] T. Mekhail,et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] F. Blanco-Vaca,et al. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility , 2004, Current opinion in lipidology.
[21] T. Kang,et al. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons , 2003, Proteomics.
[22] Ewout W Steyerberg,et al. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. , 2003, Journal of clinical epidemiology.
[23] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[24] Y. Tomita,et al. Significance of serum amyloid a on the prognosis in patients with renal cell carcinoma , 2001, Cancer.
[25] I. Glojnarić,et al. Serum Amyloid A Protein (SAA) in Colorectal Carcinoma , 2001, Clinical chemistry and laboratory medicine.
[26] M Mazumdar,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Pras,et al. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. , 1986, Journal of clinical pathology.
[28] L. Sullivan,et al. Serum amyloid A to monitor cancer dissemination. , 1979, Annals of internal medicine.
[29] L. Schwartz,et al. NCCN clinical practice guidelines in oncology: kidney cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[30] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] H. Akaike,et al. Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .
[32] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.